Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 8/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.51 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.41 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | CCND2 | P30279 | 1/20 | 0.41 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3388652 | 0.85 | TBK1 (0.49) | TBK1PDPK1CDC7CDK19CCNT1 | |
| SCHEMBL13431858 | 0.82 | TBK1 (0.72) | TBK1PDPK1CDK2 | |
| SCHEMBL3383879 | 0.81 | TBK1 (0.69) | TBK1PDPK1NTRK1 | |
| SCHEMBL3387818 | 0.80 | TBK1 (0.73) | TBK1PDPK1 | |
| Trifluoroacetic Acid SCHEMBL3388234 | 0.76 | TBK1 (0.63) | TBK1PDPK1NTRK1 | |
| SCHEMBL3389097 | 0.74 | CNR2 (0.34) | CNR2 | |
| SCHEMBL13431859 | 0.72 | TBK1 (0.73) | TBK1PDPK1CDK2 | |
| SCHEMBL13460229 | 0.72 | TBK1 (0.64) | TBK1PDPK1 | |
| SCHEMBL13431760 | 0.71 | TBK1 (0.73) | TBK1PDPK1 | |
| SCHEMBL13431757 | 0.71 | TBK1 (0.79) | TBK1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056524-A1 | Compound | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-03-04 | — | — | US | disclosed |
| WO-2009122180-A1 | PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES | MEDICAL RESEARCH COUNCIL (GB) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056524-A1 | Compound | NR3C2, NR3C1, NR2E3 | TBK1 2898/4885PDPK1 2468/4885CDC7 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.